Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,886 total articles
STMicroelectronics introduces the VD55G4 and VD65G4, new ultralow-power global-shutter image sensors designed for next-generation personal electronics such as wearables, AR/VR headsets, smart home appliances, and medical devices. These sensors deliver always-on vision capabilities with up to 10x lower power consumption, enabling extended battery li…
Qfin Holdings, Inc., a leading AI-powered Credit-Tech platform in China, released its 2025 ESG report highlighting its environmental sustainability efforts, social responsibility initiatives, and corporate governance improvements. The company remains dedicated to making credit services accessible and personalized through technology for financial in…
Volaris reported a 14% increase in total operating revenues to $770 million for Q1 2026 driven by higher fares and ancillary revenues. However, the company posted a net loss of $71 million, impacted by a 16% rise in fuel costs and increased operating expenses. Passenger demand remained solid, particularly in international markets, while capacity gr…
Telix Pharmaceuticals announced an upcoming educational webinar highlighting advancements in PSMA-targeted radionuclide therapy, featuring data from the OPTIMAL-PSMA2 trial of their novel candidate TLX597-Tx. The webinar aims to discuss the potential of Telix's differentiated multi-product approach to treating prostate cancer and facilitate patient…
MediciNova announced that a peer-reviewed study identified MIF-CD74 signaling as a vulnerability in brain metastasis and demonstrated that its drug candidate MN-166 (ibudilast) can pharmacologically inhibit this pathway to suppress metastatic progression. The study supports biomarker-driven clinical strategies, opening new therapeutic avenues for b…
Qfin Holdings, a leading AI-driven credit technology platform in China, has filed its 2025 annual report on Form 20-F with the U.S. SEC and published a corresponding report for the Hong Kong Stock Exchange. The reports include audited financial statements and reflect the company's continued efforts in leveraging AI and machine learning to enhance c…
Churchill Capital Corp XII announced the pricing of its upsized initial public offering of 36 million units at $10.00 per unit, totaling $360 million. The units will trade on Nasdaq under the ticker CXIIU, with plans for separate trading of Class A shares (CXII) and warrants (CXIIW) after the offering closes on April 29, 2026. Founded by Michael Kl…
Five Star Bancorp announced its first quarter 2026 financial results, showing net income of $18.6 million, up from $17.6 million in the prior quarter and $13.1 million year-over-year. The company reported improved earnings per share, increased loans and deposits, better net interest margin, and declared an increased cash dividend of $0.25 per share…
Global Ship Lease, Inc. announced its Annual Meeting of Shareholders for June 17, 2026, discussing director elections, ratification of its auditing firm, and corporate charter amendments. The company highlighted its fleet status and charter agreements, noting stable contracted revenue and charter durations.
NOV Inc. announced its first quarter 2026 financial results showing $2.05 billion in revenue, a 2% decrease year-over-year, with net income down to $19 million. Operational challenges due to the Middle East conflict negatively impacted revenue and profitability by approximately $54 million and $32 million respectively. Despite these setbacks, NOV s…
Performance Shipping Inc., a global tanker vessel operator, has filed its 2025 Annual Report on Form 20-F containing audited financial statements with the U.S. SEC, making it accessible for investors and shareholders.
Biomea Fusion announced positive 52-week results from its Phase 2 COVALENT-112 trial evaluating icovamenib in type 1 diabetes patients. The treatment showed a 52% increase in C-peptide levels at 12 weeks in patients diagnosed within 3 years, with durable effects preserved through 52 weeks after only a 12-week dosing period. The drug was well tolera…
Heron Therapeutics, a commercial-stage biotechnology company, will report its first quarter 2026 financial results on May 11, 2026. The company will host a conference call and webcast to discuss these results along with recent business highlights. Investors can access the call via phone or through the company's website, where an archive will be ava…
Taysha Gene Therapies announced new preclinical data demonstrating that their TSHA-102 gene therapy, based on self-complementary AAV9 delivering a miniaturized MECP2 transgene, achieves approximately 30-fold higher MeCP2 protein expression compared to a single-stranded AAV9 construct in neuronal models. These results validate the design of TSHA-102…
Lexeo Therapeutics announced multiple presentations at the 29th ASGCT Annual Meeting featuring new data on its cardiac gene therapy pipeline, including TNNI3 cardiomyopathy and Friedreich ataxia treatments, as well as advances in AAV manufacturing technology. The presentations highlight the company's innovative approaches and ongoing clinical trial…
Crinetics Pharmaceuticals announced that the European Commission has approved PALSONIFY® (paltusotine) for the treatment of acromegaly in adults, representing the first once-daily oral therapy approved in the EU. This approval is based on robust clinical data from two pivotal Phase 3 trials demonstrating efficacy, safety, and symptom improvement. W…
North American Construction Group Ltd. (NACG) will release its Q1 2026 financial results on May 13, 2026, followed by a conference call and webcast on May 14, 2026. The company provides heavy civil construction and mining services across Australia, Canada, and the U.S., serving mining, resource, and infrastructure construction markets.
Cabaletta Bio announced multiple presentations at the ASGCT 2026 Annual Meeting showcasing clinical, translational, and manufacturing data on rese-cel, their investigational CAR T cell therapy for autoimmune diseases. Highlights include early clinical data without preconditioning, automated manufacturing advances, and single-cell profiling across v…
Auddia Inc., a US-based technology company specializing in AI-driven audio identification and classification, announced the closing of its $12 million public offering. The offering included common stock and warrants, aiming to support the company's working capital and general corporate purposes as it advances its audio AI platform and music promoti…
Aclaris Therapeutics announced it will release the full results of its Phase 1a trials for its anti-TSLP/IL-4R bispecific antibody ATI-052 and disclose the lead indication chosen for its ITK/JAK3 inhibitor ATI-2138. The company plans a webcast and conference call on April 28, 2026, to discuss these data and updates ahead of market open.
First Bank reported first quarter 2026 net income of $7.6 million, down from $9.4 million in the prior year period, driven by elevated credit loss expenses primarily related to its small business portfolio. The bank experienced modest growth in loans and deposits and maintained a strong and stable net interest margin of 3.69%. Despite increased non…
Dyne Therapeutics announced upcoming presentation of new preclinical data demonstrating its FORCE platform's ability to cross the blood-brain barrier and effectively knockdown MAPT RNA in the central nervous system of nonhuman primates and mice. This breakthrough highlights the platform's potential applications beyond neuromuscular diseases into ne…
Voyager Therapeutics announced eight presentations at ASGCT 2026 including a late-breaking oral presentation highlighting the safety and pharmacology of VY1706, its IV-delivered tau-silencing gene therapy targeting Alzheimer's disease. The company plans to submit an IND in Q2 2026 and initiate first-in-human dosing in the second half of 2026. Addit…
Editas Medicine announced upcoming presentations of new preclinical data for EDIT-401, their lead in vivo CRISPR gene editing candidate, demonstrating its potential as a transformative treatment for hyperlipidemia and related cardiovascular diseases. These presentations will occur across multiple prestigious scientific conferences in May 2026, high…
Montauk Renewables, a NASDAQ-listed renewable energy company, announced its first quarter 2026 earnings conference call to be held on May 7, 2026. The company specializes in converting biogas into renewable natural gas and renewable electricity, operating multiple projects across several U.S. states. Financial results will be released prior to the …
